A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.

To be considered for this study, you would need to have a confirmed diagnosis of AL amyloidosis that affects at least one organ in your body. Your AL amyloidosis must also have either returned after previous treatment or not responded to it, and there needs to be a measurable amount of the disease in your blood.

There are also some health requirements, such as generally being well enough to take part and not having certain other medical conditions. For example, you wouldn't be able to join if you have another type of amyloidosis, severe heart or lung problems, or certain types of blood cancer. You also can't have had similar cell therapies or certain other treatments in the recent past.

If you are a woman who could become pregnant, you would need a negative pregnancy test before starting treatment and agree to use effective birth control throughout the study. Men also need to agree to use effective birth control during the study.

If you decide to participate in this study, you will receive the investigational treatment, AZD0120. This will involve regular visits to the study clinic for assessments. These assessments will likely include blood tests, physical examinations, and other tests to monitor your health and how the treatment is affecting you and your AL amyloidosis. You will need to carefully follow the study schedule and requirements.

The specific duration of your participation will depend on the study plan and your individual response, but there will be an initial treatment period followed by ongoing monitoring and follow-up visits. You will have a study team to guide you through the process, answer your questions, and monitor your well-being closely.